Jun. 3 at 2:39 PM
$CRIS HCW Analyst 6/2/25:
“ASCO 2025 highlighted the significant pharmacokinetic properties of emavusertib, showing a dose-dependent increase in cerebrospinal fluid and plasma concentrations, which is crucial for its efficacy.
Furthermore, the targeted sequencing of patients in the study revealed a distinct mutational profile among responders, with mutations in genes such as TP53, GALNT12, WT1, and BMPR1A. These findings not only enhance the understanding of emavusertib’s clinical activity but also suggest its broader potential in treating lymphoma patients”
